{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002453","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.458045+00:00","generated_at":"2026-06-03T00:17:35.910116+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Arbutus reports Q1 2024 net loss of $17.9M, cash runway extended to Q2 2026","bullets":["Net loss $17.9M ($0.10 per share); revenue $1.5M, down from $6.7M YoY due to lower license and royalty revenue.","Cash, equivalents & marketable securities $137.9M; expects cash runway through Q2 2026.","End-of-treatment data for two Phase 2a imdusiran trials to be presented at EASL June 2024.","AB-101 oral PD-L1 inhibitor Part 1 showed dose-dependent receptor occupancy; moving to multiple-ascending dose part.","Favorable claim construction ruling in Moderna LNP lawsuit; trial set for April 21, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002453","json":"https://secwatch.observer/filing/0001171843-24-002453.json","markdown":"https://secwatch.observer/filing/0001171843-24-002453.md","text":"https://secwatch.observer/filing/0001171843-24-002453.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324002453/0001171843-24-002453-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324002453/f8k_050224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:17:35.910116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c9cd395fd43398be4906ce186034a12d4944ca23","claim":"Arbutus Biopharma Corp reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 2, 2024, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024 and certain other information.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324002453/0001171843-24-002453-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}